Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$3.40 USD
+0.04 (1.19%)
Updated May 8, 2024 04:00 PM ET
After-Market: $3.39 -0.01 (-0.29%) 7:52 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ABOS 3.40 +0.04(1.19%)
Will ABOS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABOS
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
ABOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Other News for ABOS
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen announces first patient dosed in ALTITUDE-AD study
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts